Microbot Medical® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular Robotic System
Microbot Medical (Nasdaq: MBOT) announced a U.S.-based third-party logistics partnership to support commercialization of the FDA-cleared LIBERTY Endovascular Robotic System.
The company expects a limited market release in Q4 2025 and a broader commercial launch in April 2026 during the Society of Interventional Radiology conference. The 3PL partner offers integrated fulfillment, proximity to key markets, effective order processing, inventory maintenance, and a strategically located climate-controlled warehouse to meet expected demand.
Microbot Medical (Nasdaq: MBOT) ha annunciato una partnership logistica con un fornitore terzo con sede negli Stati Uniti per supportare la commercializzazione del Sistema Robotico Endovascolare LIBERTY, approvato dalla FDA.
L'azienda prevede un rilascio limitato sul mercato nel quarto trimestre del 2025 e un lancio commerciale più ampio nell'aprile 2026 durante la conferenza della Society of Interventional Radiology. Il partner 3PL offre gestione integrata degli ordini, prossimità ai mercati chiave, gestione efficiente dell'inventario e un magazzino climatizzato strategicamente posizionato per soddisfare la domanda prevista.
Microbot Medical (Nasdaq: MBOT) anunció una asociación logística externa con sede en EE. UU. para apoyar la comercialización del Sistema Robótico Endovascular LIBERTY, aprobado por la FDA.
La empresa prevé un lanzamiento limitado al mercado en el cuarto trimestre de 2025 y un lanzamiento comercial más amplio en abril de 2026 durante la conferencia de la Sociedad de Radiología Intervencionista. El socio 3PL ofrece fulfillment integrado, proximidad a mercados clave, procesamiento de pedidos eficiente, mantenimiento de inventario y un almacén climatizado estratégicamente ubicado para satisfacer la demanda prevista.
마이크로봇 메디컬(Microbot Medical, 나스닥: MBOT)은 FDA 승인 LIBERTY 혈관 내 로봇 시스템의 상용화를 지원하기 위한 미국 기반의 제3자 물류 파트너십을 발표했습니다.
회사는 2025년 4분기에 한정된 시장 출시를 예상하고, 2026년 4월에 더 넓은 상용 출시를 Society of Interventional Radiology 컨퍼런스 기간에 계획하고 있습니다. 이 3PL 파트너는 통합 주문 처리, 주요 시장에의 근접성, 효율적인 주문 처리, 재고 유지 및 수요를 충족하기 위한 전략적으로 배치된 기후 제어 물류창고를 제공합니다.
Microbot Medical (Nasdaq : MBOT) a annoncé un partenariat logistique basé aux États-Unis pour soutenir la commercialisation du Système Robotique Endovasculaire LIBERTY, approuvé par la FDA.
L'entreprise prévoit une sortie sur le marché limitée au T4 2025 et un lancement commercial plus large en avril 2026 lors de la conférence de la Society of Interventional Radiology. Le partenaire 3PL offre une exécution intégrée, une proximité avec les marchés clés, un traitement des commandes efficace, la maintenance des stocks et un entrepôt climatisé stratégiquement situé pour répondre à la demande prévue.
Microbot Medical (Nasdaq: MBOT) kündigte eine US-basierte Drittanbieter-Logistikpartnerschaft zur Unterstützung der Kommerzialisierung des FDA-zugelassenen LIBERTY Endovascular Robotic System an.
Das Unternehmen erwartet eine begrenzte Markteinführung im Q4 2025 und eine breitere kommerzielle Markteinführung im April 2026 während der Konferenz der Society of Interventional Radiology. Der 3PL-Partner bietet integriertes Fulfillment, Nähe zu wichtigen Märkten, effektive Auftragsabwicklung, Bestandsführung und ein strategisch gelegenes klimatisiertes Lager, um die erwartete Nachfrage zu decken.
Microbot Medical (Nasdaq: MBOT) أعلنت عن شراكة لوجستية مع طرف ثالث مقره الولايات المتحدة للمساعدة في تسويق N LIBERTY دوائية Endovascular Robotic System المعتمد من FDA.
تتوقع الشركة إصداراً محدوداً في السوق في الربع الرابع 2025 وإطلاقاً تجارياً أوسع في أبريل 2026 خلال مؤتمر جمعية الأشعة التدخلية. الشريك من الطرف الثالث (3PL) يوفر تلبية متكاملة للطلبات، والقرب من الأسواق الرئيسية، ومعالجة الطلبات بشكل فعال، وصيانة المخزون، ومستودعاً مكيّفاً يقع في موقع استراتيجي لتلبية الطلب المتوقع.
Microbot Medical（纳斯达克：MBOT） 宣布与一家美国基地的第三方物流合作伙伴，以支持FDA 批准的 LIBERTY 腔内机器人系统的商业化。
公司预计在2025 年第四季度实现有限市场发布，并在2026 年 4 月于介入放射学会会议期间进行更广泛的商业启动。该3PL伙伴提供一体化履约、靠近关键市场、高效的订单处理、库存维护，以及位于战略位置、具气候控制的仓库，以满足预期需求。
- FDA-cleared LIBERTY System
- Limited market release expected in Q4 2025
- Broader commercial launch planned in April 2026
- U.S. 3PL partner with climate-controlled warehouse
- 3PL provides integrated fulfillment and inventory management
- None.
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support
The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year
HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, has partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of the FDA-cleared LIBERTY® System. The Company is expected to initiate the limited market release of the LIBERTY® System during the current fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology conference, which is the largest Interventional Radiology conference in the U.S.
The 3PL company is a fully compliant and integrated fulfillment solutions provider specializing in the medical device industry, which would allow the Company to leverage its proximity to key markets, and provide effective and efficient order processing and the ability to maintain inventory to meet expected demand from a strategically located, climate-controlled warehouse.
“As we continue to establish the infrastructure to support the commercial launch of LIBERTY following FDA clearance, we believe that having an established logistics provider with deep medtech expertise puts us in a stronger position to achieve our go-to-market initiatives more efficiently,” commented Michal Ahuvia, Director of Operations.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
When will Microbot Medical (MBOT) begin commercial sales of the LIBERTY system?
What does the MBOT logistics partnership provide for the LIBERTY launch?
Is the LIBERTY Endovascular Robotic System approved for use in the U.S.?
Where will Microbot Medical promote the broader LIBERTY launch in April 2026?
How does the 3PL arrangement affect MBOT's readiness for launch?
Will the LIBERTY limited release in Q4 2025 be nationwide for MBOT?
